Table 4 CRF identification and management by rheumatologists in RA; PCPs in RA, DM, and the GP
| Â | Â | Group A (RA) Rh | Group A (RA) PCP | Group B (DM) | Group C (GP) | P, Group A (Rh versus PCP) | P, all three (PCP) | P, A versus C (PCP) |
|---|---|---|---|---|---|---|---|---|
Smoking | ID | 52 (21%) | 167 (67%) | 161 (64%) | 188 (75%) | < 0.0001 | 0.02 | 0.0496 |
| Â | MA | 32 (13%) | 25 (10%) | 28 (11%) | 39 (16%) | 0.4 | 0.1 | 0.08 |
Weight | ID | 67 (27%) | 111 (44%) | 191 (76%) | 136 (54%) | < 0.0001 | < 0.0001 | 0.03 |
| Â | MA | 15 (6%) | 72 (29%) | 159 (63%) | 99 (39%) | < 0.0001 | < 0.0001 | 0.01 |
BP | ID | 233 (93%) | 243 (97%) | 250 (99.6%) | 250 (99.6%) | 0.07 | Â | 0.04 |
| Â | MA | 14 (6%) | 53 (21%) | 169 (67%) | 80 (32%) | < 0.0001 | < 0.0001 | 0.008 |
HDL | ID | 13 (5%) | 109 (43%) | 190 (76%) | 144 (57%) | < 0.0001 | < 0.0001 | 0.002 |
| Â | MA | 5 (2%) | 34 (14%) | 137 (55%) | 70 (28%) | < 0.0001 | < 0.0001 | 0.0001 |
LDL | ID | 14 (6%) | 110 (44%) | 197(79%) | 146 (58%) | < 0.0001 | < 0.0001 | 0.004 |
| Â | MA | 4 (2%) | 38 (15%) | 160 (64%) | 78 (31%) | < 0.0001 | < 0.0001 | < 0.0001 |
TG | ID | 14 (6%) | 109 (43%) | 190 (76%) | 141 (56%) | < 0.0001 | < 0.0001 | 0.006 |
| Â | MA | 5 (2%) | 36 (14%) | 142 (57%) | 70 (28%) | < 0.0001 | < 0.0001 | 0.0003 |
FBG | ID | 3 (1%) | 58 (23%) | 237 (94%) | 68 (27%) | < 0.0001 | < 0.0001 | 0.4 |
| Â | MA | 0 | 7 (3%) | 232 (92%) | 19 (8%) | 0.02 | < 0.0001 | 0.03 |